Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick, Piscataway, NJ, USA.
Department of Neurology, University of Chicago, Chicago, IL, USA.
Neurotherapeutics. 2021 Jul;18(3):1650-1653. doi: 10.1007/s13311-021-01107-5. Epub 2021 Aug 18.
Many autoimmune diseases confer a higher risk of cancer on patients compared to the general population. A controversial factor tying autoimmune diseases to malignancy is harm from immunosuppressive treatment. Nonetheless, multiple sclerosis is different from other autoimmune diseases, and findings from other disease populations may not apply. In this issue of Neurotherapeutics, Dolladile and colleagues from France present new evidence about the risks of cancers in patients with multiple sclerosis treated with disease-modifying therapies based on analyses of spontaneous reporting data. This commentary discusses the context, limitations, and implications of these findings.
许多自身免疫性疾病使患者罹患癌症的风险高于一般人群。将自身免疫性疾病与恶性肿瘤联系起来的一个有争议的因素是免疫抑制治疗的危害。然而，多发性硬化症不同于其他自身免疫性疾病，其他疾病人群的发现可能并不适用。在本期《神经治疗学》中，来自法国的 Dolladile 及其同事基于自发报告数据的分析，就多发性硬化症患者接受疾病修正治疗的癌症风险提出了新的证据。本评论讨论了这些发现的背景、局限性和意义。
